AI Drug Discovery Moves from Data Platforms toward Clinical Pipelines

Enveda’s reported $311M Series E at a $2B valuation and Basecamp Research’s $140M Series C at approximately $800M show investors backing AI-biotech companies with therapeutic programs, not only software platforms. Early clinical readouts and expanding pipelines strengthen the platform-to-drugs narrative, but efficacy, regulatory progress and commercialization remain unproven.